Produktname:3-bromo-5-nitrobenzoic acid
IUPAC Name:3-bromo-5-nitrobenzoic acid
- CAS：6307-83-1
- Molekulare Formel：C7H4BrNO4
- Reinheit：95%+
- Katalognummer：CM108344
- Molekulargewicht：246.02
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:6307-83-1
- Molekulare Formel:C7H4BrNO4
- Schmelzpunkt:-
- SMILES-Code:O=C(O)C1=CC([N+]([O-])=O)=CC(Br)=C1
- Dichte:
- Katalognummer:CM108344
- Molekulargewicht:246.02
- Siedepunkt:
- Mdl-Nr.:MFCD00100098
- Lagerung:
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Carbonyl Compounds
- In organic chemistry, a carbonyl group is a functional group with the formula C=O, composed of a carbon atom double-bonded to an oxygen atom, and it is divalent at the C atom. It is common to several classes of organic compounds (such as aldehydes, ketones and carboxylic acids), as part of many larger functional groups. A compound containing a carbonyl group is often referred to as a carbonyl compound.
- Tuspetinib
- Venetoclax (VEN) combined with a hypomethylating agent (HMA) has proven effective for treating acute myeloid leukemia (AML) patients who are ineligible for intensive chemotherapy. However, this combination therapy still faces issues such as low response rates, limited survival, and potential resistance to VEN.
Aptose’s Tuspetinib (TUS) is a multi-kinase inhibitor selectively targeting SYK, RSK, FLT3 , JAK1/2, KIT, which drive proliferation in AML. The addition of Tuspetinib into VEN and HMA therapy improves medical efficacy and and may help prevent resistance to both agents. TUS+VEN+HMA triplet protocol in frontline therapy for newly diagnosed (ND) AML is currently being tested in a global phase 1/2 trial.
Suche 
+86 21 5895 0110 
